Ru(II)/amino acid complexes inhibit the progression of breast cancer cells through multiple mechanism-induced apoptosis

Autor: Francyelli Mello-Andrade, Carlos Frederico Martins Menck, Vivianne S. Velozo-Sa, Clever C. Gomes, Vivek M. Rangnekar, Davi Mendes, Larissa Matuda, Alzir A. Batista, Ravshan Burikhanov, Wanessa Carvalho Pires, Paulo Roberto de Melo-Reis, Kezia A. Delmond, Matheus S. Molina, Maria Alice Montes de Sousa, Elisângela de Paula Silveira-Lacerda, Marcio Aurélio Pinheiro Almeida, Carlos Henrique de Castro, Adriana P. M. Guedes
Rok vydání: 2022
Předmět:
Zdroj: Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Popis: For some cancer subtypes, such as triple-negative breast cancer, there are no specific therapies, which leads to a poor prognosis associated with invasion and metastases. Ruthenium complexes have been developed to act in all steps of tumor growth and its progression. In this study, we investigated the effects of Ruthenium (II) complexes coupled to the amino acids methionine (RuMet) and tryptophan (RuTrp) on the induction of cell death, clonogenic survival ability, inhibition of angiogenesis, and migration of MDA-MB-231 cells (human triple-negative breast cancer). The study also demonstrated that the RuMet and RuTrp complexes induce cell cycle blockage and apoptosis of MDA-MB-231 cells, as evidenced by an increase in the number of Annexin V-positive cells, p53 phosphorylation, caspase 3 activation, and poly(ADP-ribose) polymerase cleavage. Moreover, morphological changes and loss of mitochondrial membrane potential were detected. The RuMet and RuTrp complexes induced DNA damage probably due to reactive oxygen species production related to mitochondrial membrane depolarization. Therefore, the RuMet and RuTrp complexes acted directly on breast tumor cells, leading to cell death and inhibiting their metastatic potential; this reveals the potential therapeutic action of these drugs.
Databáze: OpenAIRE